Merck (MRK) to Take $2.9B Pre-Tax Impairment Charge on HCV Drug
Tweet Send to a Friend
Merck (NYSE: MRK) determined that it will record an intangible asset impairment charge related to the research program for MK-3682 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
